A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity




TekijätNygardas M, Paavilainen H, Muther N, Nagel CH, Roytta M, Sodeik B, Hukkanen V

KustantajaPUBLIC LIBRARY SCIENCE

Julkaisuvuosi2013

JournalPLoS ONE

Tietokannassa oleva lehden nimiPLOS ONE

Lehden akronyymiPLOS ONE

Artikkelin numeroARTN e64200

Numero sarjassa6

Vuosikerta8

Numero6

Sivujen määrä14

ISSN1932-6203

DOIhttps://doi.org/10.1371/journal.pone.0064200


Tiivistelmä
Herpes simplex virus type 1 (HSV-1) has properties that can be exploited for the development of gene therapy vectors. The neurotropism of HSV enables delivery of therapeutic genes to the nervous system. Using a bacterial artificial chromosome (BAC), we constructed an HSV-1(17(+))-based replicative vector deleted of the neurovirulence gene gamma(1)34.5, and expressing leukemia inhibitory factor (LIF) as a transgene for treatment of experimental autoimmune encephalomyelitis (EAE). EAE is an inducible T-cell mediated autoimmune disease of the central nervous system (CNS) and is used as an animal model for multiple sclerosis. Demyelination and inflammation are hallmarks of both diseases. LIF is a cytokine that has the potential to limit demyelination and oligodendrocyte loss in CNS autoimmune diseases and to affect the T-cell mediated autoimmune response. In this study SJL/J mice, induced for EAE, were treated with a HSV-LIF vector intracranially and the subsequent changes in disease parameters and immune responses during the acute disease were investigated. Replicating HSV-LIF and its DNA were detected in the CNS during the acute infection, and the vector spread to the spinal cord but was non-virulent. The HSV-LIF significantly ameliorated the EAE and contributed to a higher number of oligodendrocytes in the brains when compared to untreated mice. The HSV-LIF therapy also induced favorable changes in the expression of immunoregulatory cytokines and T-cell population markers in the CNS during the acute disease. These data suggest that BAC-derived HSV vectors are suitable for gene therapy of CNS disease and can be used to test the therapeutic potential of immunomodulatory factors for treatment of EAE.



Last updated on 2024-26-11 at 20:51